Back

Risk prediction in ATTR-CM patients under tafamidis treatment: results from the multicentre SWISS-CARE registry

28 August 2026 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: Diagnosis and risk stratification in cardiac amyloidosis Infiltrative Myocardial Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Moritz Jens Hundertmark

Bern University Hospital, Inselspital, Bern (Switzerland)

6 More presentations in this session

Presentation thumbnail
Lymphocyte-to–C-reactive-protein ratio is a strong predictor of mortality risk in cardiac transthyretin amyloidosis
Mr V. Cejka (Wurzburg, DE)
Abstract Slides Video
Presentation thumbnail
Idiopathic carpal tunnel syndrome as an early clinical indicator of transthyretin cardiac amyloidosis: diagnostic insights
Doctor E. Martins (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Transthyretin gene variants in a population-based study of 9,957 Finnish men and in 366 Finnish patients with hypertrophic cardiomyopathy
Doctor T. Pennanen (Kuopio, FI)
Abstract Slides Video
Presentation thumbnail
Safety, diagnostic yield and clinical utility of endomyocardial biopsy in patients with suspected cardiac amyloidosis: a 10-year consecutive single-centre experience
Doctor J. Mansell (London, GB)
Abstract Slides Video
Presentation thumbnail
Ventricular arrhythmias in ATTR-CM: frequency, disease severity and risk of sudden cardiac death
Doctor K. Knoll (Munich, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Diagnosis and risk stratification in cardiac amyloidosis

The Event

Event poster

ESC Congress 2026

28 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Clinical impact of atrial fibrillation on cardiac parameters and long-term outcomes in patients with transthyretin amyloid cardiomyopathy in the era of disease-modifying therapy
28 August 2026
thumbnail
Congress Presentation
Turning data into decisions: insights from trials and real-world experience in ATTR-CM
12 December 2025
thumbnail
Congress Presentation
Do tafamidis and acoramidis improve survival and cardiovascular outcomes in transthyretin amyloid cardiomyopathy? a systematic review and meta-analysis
30 August 2026
thumbnail
Congress Presentation
Long-term improvement in myocardial structure and function in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with acoramidis compared with a natural history cohort
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources